Sellas Life Sciences Group Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.27
- Today's High:
- $1.38
- Open Price:
- $1.37
- 52W Low:
- $1.27
- 52W High:
- $7.4
- Prev. Close:
- $1.38
- Volume:
- 331100
Company Statistics
- Market Cap.:
- $38.38 million
- Book Value:
- 0.231
- Revenue TTM:
- $1 million
- Operating Margin TTM:
- -3195%
- Gross Profit TTM:
- $900000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -84.58%
- Return on Equity TTM:
- -327.81%
Company Profile
Sellas Life Sciences Group Inc had its IPO on 2017-12-29 under the ticker symbol SLS.
The company operates in the Healthcare sector and Biotechnology industry. Sellas Life Sciences Group Inc has a staff strength of 0 employees.
Stock update
Shares of Sellas Life Sciences Group Inc opened at $1.37 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $1.27 - $1.38, and closed at $1.35.
This is a -2.17% slip from the previous day's closing price.
A total volume of 331,100 shares were traded at the close of the day’s session.
In the last one week, shares of Sellas Life Sciences Group Inc have slipped by -4.26%.
Sellas Life Sciences Group Inc's Key Ratios
Sellas Life Sciences Group Inc has a market cap of $38.38 million, indicating a price to book ratio of 3.7918 and a price to sales ratio of 47.7646.
In the last 12-months Sellas Life Sciences Group Inc’s revenue was $1 million with a gross profit of $900000 and an EBITDA of $0. The EBITDA ratio measures Sellas Life Sciences Group Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sellas Life Sciences Group Inc’s operating margin was -3195% while its return on assets stood at -84.58% with a return of equity of -327.81%.
In Q4, Sellas Life Sciences Group Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 82.5%.
Sellas Life Sciences Group Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sellas Life Sciences Group Inc’s profitability.
Sellas Life Sciences Group Inc stock is trading at a EV to sales ratio of 27.4527 and a EV to EBITDA ratio of -0.6222. Its price to sales ratio in the trailing 12-months stood at 47.7646.
Sellas Life Sciences Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $20.94 million
- Total Liabilities
- $15.52 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Sellas Life Sciences Group Inc ended 2023 with $20.94 million in total assets and $0 in total liabilities. Its intangible assets were valued at $20.94 million while shareholder equity stood at $4.85 million.
Sellas Life Sciences Group Inc ended 2023 with $0 in deferred long-term liabilities, $15.52 million in other current liabilities, 2000.00 in common stock, $-179904000.00 in retained earnings and $1.91 million in goodwill. Its cash balance stood at $17.13 million and cash and short-term investments were $17.13 million. The company’s total short-term debt was $372,000 while long-term debt stood at $0.
Sellas Life Sciences Group Inc’s total current assets stands at $17.76 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $3.36 million and inventory worth $0.
In 2023, Sellas Life Sciences Group Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Sellas Life Sciences Group Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.35
- 52-Week High
- $7.4
- 52-Week Low
- $1.27
- Analyst Target Price
- $8.25
Sellas Life Sciences Group Inc stock is currently trading at $1.35 per share. It touched a 52-week high of $7.4 and a 52-week low of $7.4. Analysts tracking the stock have a 12-month average target price of $8.25.
Its 50-day moving average was $2.71 and 200-day moving average was $2.74 The short ratio stood at 2.01 indicating a short percent outstanding of 0%.
Around 37.7% of the company’s stock are held by insiders while 781.1% are held by institutions.
Frequently Asked Questions About Sellas Life Sciences Group Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.